0001193125-15-273235.txt : 20150803 0001193125-15-273235.hdr.sgml : 20150801 20150731180258 ACCESSION NUMBER: 0001193125-15-273235 CONFORMED SUBMISSION TYPE: 497K PUBLIC DOCUMENT COUNT: 5 FILED AS OF DATE: 20150803 DATE AS OF CHANGE: 20150731 EFFECTIVENESS DATE: 20150803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iSHARES TRUST CENTRAL INDEX KEY: 0001100663 IRS NUMBER: 943351276 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 497K SEC ACT: 1933 Act SEC FILE NUMBER: 333-92935 FILM NUMBER: 151020444 BUSINESS ADDRESS: STREET 1: 400 HOWARD STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94105 BUSINESS PHONE: (415) 670-2000 MAIL ADDRESS: STREET 1: 400 HOWARD STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94105 FORMER COMPANY: FORMER CONFORMED NAME: ISHARES TRUST DATE OF NAME CHANGE: 19991213 0001100663 S000004372 iShares Global Healthcare ETF C000012102 iShares Global Healthcare ETF IXJ 497K 1 d60307d497k.htm FORM 497K Form 497K
August 1, 2015
2015 Summary Prospectus
►  iShares Global Healthcare ETF | IXJ |  NYSE ARCA
Before you invest, you may want to review the Fund’s prospectus, which contains more information about the Fund and its risks. You can find the Fund’s prospectus (including amendments and supplements) and other information about the Fund, including the Fund’s statement of additional information and shareholder report, online at http://us.ishares.com/prospectus. You can also get this information at no cost by calling 1-800-iShares (1-800-474-2737) or by sending an e-mail request to iSharesETFs@blackrock.com, or from your financial professional. The Fund’s prospectus and statement of additional information, both dated August 1, 2015, as amended and supplemented from time to time, are incorporated by reference into (legally made a part of) this Summary Prospectus.
The Securities and Exchange Commission (“SEC”) has not approved or disapproved these securities or passed upon the adequacy of this prospectus. Any representation to the contrary is a criminal offense.

iSHARES® GLOBAL HEALTHCARE ETF
Ticker: IXJ Stock Exchange: NYSE Arca
Investment Objective
The iShares Global Healthcare ETF (the “Fund”) seeks to track the investment results of an index composed of global equities in the healthcare sector.
Fees and Expenses
The following table describes the fees and expenses that you will incur if you own shares of the Fund. The investment advisory agreement between iShares Trust (the “Trust”) and BlackRock Fund Advisors (“BFA”) (formerly, Barclays Global Fund Advisors (“BGFA”)) (the “Investment Advisory Agreement”) provides that BFA will pay all operating expenses of the Fund, except interest expenses, taxes, brokerage expenses, future distribution fees or expenses, and extraordinary expenses.
You may also incur usual and customary brokerage commissions and other charges when buying or selling shares of the Fund, which are not reflected in the Example that follows:
Annual Fund Operating Expenses
(ongoing expenses that you pay each year as a
percentage of the value of your investments)
Management
Fees 		  Distribution and
Service (12b-1)
Fees 		  Other
Expenses 		  Total Annual
Fund
Operating
Expenses
0.47%   None   None   0.47%
Example. This Example is intended to help you compare the cost of owning shares of the Fund with the cost of investing in other funds. The Example assumes that you invest $10,000 in the Fund for the time periods indicated and then sell all of your shares at the end of those periods. The Example also assumes that your investment has a 5% return each year and that the Fund’s operating expenses remain the same. Although your actual costs may be higher or lower, based on these assumptions, your costs would be:
1 Year   3 Years   5 Years   10 Years
$48   $151   $263   $591
S-1

Portfolio Turnover. The Fund may pay transaction costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). A higher portfolio turnover rate may indicate higher transaction costs and may result in higher taxes when Fund shares are held in a taxable account. These costs, which are not reflected in Annual Fund Operating Expenses or in the Example, affect the Fund's performance. During the most recent fiscal year, the Fund's portfolio turnover rate was 3% of the average value of its portfolio.
Principal Investment Strategies
The Fund seeks to track the investment results of the S&P Global 1200 Health Care Sector IndexTM (the “Underlying Index”), which measures the performance of companies that S&P Dow Jones Indices LLC (the “Index Provider” or “SPDJI”), a subsidiary of McGraw Hill Financial, Inc., deems to be a part of the healthcare sector of the economy and that SPDJI believes are important to global markets. It is a subset of the S&P Global 1200TM. The Underlying Index may include large-, mid- or small-capitalization companies. Components of the Underlying Index primarily include biotechnology, healthcare, medical equipment and pharmaceuticals companies. The components of the Underlying Index, and the degree to which these components represent certain industries, may change over time. As of March 31, 2015, the Underlying Index was comprised of stocks of companies in the following countries: Australia, Belgium, Canada, Denmark, France, Germany, Japan, Switzerland, the United Kingdom and the United States.
BFA uses a “passive” or indexing approach to try to achieve the Fund’s investment objective. Unlike many investment companies, the Fund does not try to “beat” the index it tracks and does not seek temporary defensive positions when markets decline or appear overvalued.
Indexing may eliminate the chance that the Fund will substantially outperform the Underlying Index but also may reduce some of the risks of active management, such as poor security selection. Indexing seeks to achieve lower costs and better after-tax performance by keeping portfolio turnover low in comparison to actively managed investment companies.
BFA uses a representative sampling indexing strategy to manage the Fund. “Representative sampling” is an indexing strategy that involves investing in a representative sample of securities that collectively has an investment profile similar to that of the Underlying Index. The securities selected are expected to have, in the aggregate, investment characteristics (based on factors such as market capitalization and industry weightings), fundamental characteristics (such as return variability and yield) and liquidity measures similar to those of the Underlying Index. The Fund may or may not hold all of the securities in the Underlying Index.
The Fund generally invests at least 90% of its assets in securities of the Underlying Index and in depositary receipts representing securities of the Underlying Index. The Fund may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents, including shares of money market funds advised
S-2

by BFA or its affiliates, as well as in securities not included in the Underlying Index, but which BFA believes will help the Fund track the Underlying Index. The Fund seeks to track the investment results of the Underlying Index before fees and expenses of the Fund.
The Fund may lend securities representing up to one-third of the value of the Fund's total assets (including the value of any collateral received).
The Underlying Index is a product of SPDJI, which is independent of the Fund and BFA. The Index Provider determines the composition and relative weightings of the securities in the Underlying Index and publishes information regarding the market value of the Underlying Index.
Industry Concentration Policy. The Fund will concentrate its investments (i.e., hold 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated. For purposes of this limitation, securities of the U.S. government (including its agencies and instrumentalities) and repurchase agreements collateralized by U.S. government securities are not considered to be issued by members of any industry.
Summary of Principal Risks
As with any investment, you could lose all or part of your investment in the Fund, and the Fund's performance could trail that of other investments. The Fund is subject to the principal risks noted below, any of which may adversely affect the Fund's net asset value per share (“NAV”), trading price, yield, total return and ability to meet its investment objective.
Asset Class Risk. Securities in the Underlying Index or in the Fund's portfolio may underperform in comparison to the general financial markets, a particular financial market or other asset classes.
Authorized Participant Concentration Risk. Only an Authorized Participant (as defined in the Creations and Redemptions section of the Prospectus) may engage in creation or redemption transactions directly with the Fund. The Fund has a limited number of institutions that act as Authorized Participants. To the extent that these institutions exit the business or are unable to proceed with creation and/or redemption orders with respect to the Fund and no other Authorized Participant is able to step forward to create or redeem, in either of these cases, Fund shares may trade at a discount to NAV and possibly face delisting.
Biotechnology Industry Risk. Biotechnology companies face intense competition and the potential for rapid product obsolescence. Biotechnology companies may be adversely affected by the loss or impairment of intellectual property rights or changes in government regulations.
Concentration Risk. The Fund may be susceptible to an increased risk of loss, including losses due to adverse events that affect the Fund’s investments more than the market as a whole, to the extent that the Fund's investments are concentrated in the securities of a particular issuer or issuers, country, group of countries, region, market, industry, group of industries, sector or asset class.
Currency Risk. Because the Fund's NAV is determined in U.S. dollars, the
S-3

Fund's NAV could decline if the currency of a non-U.S. market in which the Fund invests depreciates against the U.S. dollar or if there are delays or limits on repatriation of such currency.
Equity Securities Risk. Equity securities are subject to changes in value, and their values may be more volatile than those of other asset classes.
Geographic Risk. A natural or other disaster could occur in a geographic region in which the Fund invests.
Healthcare Sector Risk. The healthcare sector may be affected by government regulations and government healthcare programs, increases or decreases in the cost of medical products and services and product liability claims, among other factors. Many healthcare companies are heavily dependent on patent protection, and the expiration of a company’s patent may adversely affect that company’s profitability. Healthcare companies are subject to competitive forces that may result in price discounting, and may be thinly capitalized and susceptible to product obsolescence.
Index-Related Risk. There is no guarantee that the Fund will achieve a high degree of correlation to the Underlying Index and therefore achieve its investment objective. Market disruptions and regulatory restrictions could have an adverse effect on the Fund’s ability to adjust its exposure to the required levels in order to track the Underlying Index. Errors in index data, index computations or the construction of the Underlying Index in accordance with its methodology may occur from time to time and may not be identified and corrected by the Index Provider for a period of time or at all, which may
have an adverse impact on the Fund and its shareholders.
Issuer Risk. Fund performance depends on the performance of individual securities to which the Fund has exposure. Changes in the financial condition or credit rating of an issuer of those securities may cause the value of the securities to decline.
Management Risk. As the Fund may not fully replicate the Underlying Index, it is subject to the risk that BFA's investment strategy may not produce the intended results.
Market Risk. The Fund could lose money over short periods due to short-term market movements and over longer periods during more prolonged market downturns.
Market Trading Risk. The Fund faces numerous market trading risks, including the potential lack of an active market for Fund shares, losses from trading in secondary markets, periods of high volatility and disruptions in the creation/redemption process. ANY OF THESE FACTORS, AMONG OTHERS, MAY LEAD TO THE FUND'S SHARES TRADING AT A PREMIUM OR DISCOUNT TO NAV.
Medical Equipment Industry Group Risk. Companies in the medical equipment industry group may be affected by the expiration of patents, litigation based on product liability, industry competition, product obsolescence and regulatory approvals, among other factors.
Non-Diversification Risk. The Fund may invest a large percentage of its assets in securities issued by or representing a small number of issuers. As a result, the Fund's performance
S-4

may depend on the performance of a small number of issuers.
Non-U.S. Securities Risk. Investments in the securities of non-U.S. issuers are subject to the risks associated with investing in those non-U.S. markets, such as heightened risks of inflation or nationalization. The Fund may lose money due to political, economic and geographic events affecting issuers of non-U.S. securities or non-U.S. markets. The Fund is specifically exposed to European Economic Risk and North American Economic Risk.
Passive Investment Risk. The Fund is not actively managed and BFA does not attempt to take defensive positions under any market conditions, including declining markets.
Pharmaceuticals Industry Risk. Companies in the pharmaceuticals industry may be affected by industry competition, dependency on a limited number of products, obsolescence of products, government approvals and regulations, loss or impairment of intellectual property rights and litigation regarding product liability.
Risk of Investing in Developed Countries. The Fund’s investment in developed country issuers may subject the Fund to regulatory, political, currency, security, economic and other risks specific to developed countries. Developed countries tend to represent a significant portion of the global economy and have generally experienced slower economic growth than some less developed countries. Many developed countries experienced a significant economic slowdown during the recent financial crisis. In addition, developed countries may be impacted by changes to the economic health of certain key trading partners, regulatory
burdens, debt burdens and the price or availability of certain commodities.
Risk of Investing in the United States. The Fund has significant exposure to U.S. issuers. Certain changes in the U.S. economy, such as when the U.S. economy weakens or when its financial markets decline, may have an adverse effect on the securities to which the Fund has exposure.
Securities Lending Risk. The Fund may engage in securities lending. Securities lending involves the risk that the Fund may lose money because the borrower of the loaned securities fails to return the securities in a timely manner or at all. The Fund could also lose money in the event of a decline in the value of the collateral provided for loaned securities or a decline in the value of any investments made with cash collateral. These events could also trigger adverse tax consequences for the Fund.
Security Risk. Some countries and regions in which the Fund invests have experienced security concerns. Incidents involving a country's or region's security may cause uncertainty in these markets and may adversely affect their economies and the Fund's investments.
Structural Risk. The countries in which the Fund invests may be subject to considerable degrees of economic, political and social instability.
Tracking Error Risk. Tracking error is the divergence of the Fund’s performance from that of the Underlying Index. Tracking error may occur because of differences between the securities or other instruments held in the Fund’s portfolio and those included in the Underlying Index, pricing differences, transaction costs, the Fund’s holding of uninvested cash, differences in timing of the accrual of
S-5

dividends or interest, tax gains or losses, changes to the Underlying Index or the need to meet various new or existing regulatory requirements. This risk may be heightened during times of increased market volatility or other unusual market conditions. Tracking error also may result because the Fund incurs fees and expenses, while the Underlying Index does not.
Valuation Risk. The sale price the Fund could receive for a security may differ
from the Fund's valuation of the
security  and from the value used by the Underlying Index, particularly for securities or assets that trade in low volume or volatile markets or that are valued using a fair value methodology. In addition, the value of the securities or assets in the Fund's portfolio may change on days when shareholders will not be able to purchase or sell the Fund's shares.
Performance Information
The bar chart and table that follow show how the Fund has performed on a calendar year basis and provide an indication of the risks of investing in the Fund. Both assume that all dividends and distributions have been reinvested in the Fund. Past performance (before and after taxes) does not necessarily indicate how the Fund will perform in the future. Supplemental information about the Fund’s performance is shown under the heading Total Return Information in the Supplemental Information section of the Fund's prospectus (the “Prospectus”).
Year-by-Year Returns1 (Years Ended December 31)
1 The Fund’s year-to-date return as of June 30, 2015 was 9.40%.
The best calendar quarter return during the periods shown above was 14.30% in the 1st quarter of 2013; the worst was -10.87% in the 2nd quarter of 2010.
Updated performance information is available at www.iShares.com or by calling 1-800-iShares (1-800-474-2737) (toll free).
S-6

Average Annual Total Returns
(for the periods ended December 31, 2014)
  One Year   Five Years   Ten Years
(Inception Date: 11/13/2001)          
Return Before Taxes 17.66%   16.33%   9.34%
Return After Taxes on Distributions1 17.26%   15.92%   9.03%
Return After Taxes on Distributions and Sale of Fund Shares1 10.30%   13.19%   7.66%
S&P Global 1200 Health Care Sector IndexTM (Index returns do not reflect deductions for fees, expenses, or taxes) 17.80%   16.37%   9.41%
1 After-tax returns in the table above are calculated using the historical highest individual U.S. federal marginal income tax rates and do not reflect the impact of state or local taxes. Actual after-tax returns depend on an investor’s tax situation and may differ from those shown, and after-tax returns shown are not relevant to tax-exempt investors or investors who hold shares through tax-deferred arrangements, such as 401(k) plans or individual retirement accounts (“IRAs”). Fund returns after taxes on distributions and sales of Fund shares are calculated assuming that an investor has sufficient capital gains of the same character from other investments to offset any capital losses from the sale of Fund shares. As a result, Fund returns after taxes on distributions and sales of Fund shares may exceed Fund returns before taxes and/or returns after taxes on distributions.
S-7

Management
Investment Adviser. BlackRock Fund Advisors.
Portfolio Managers. Matthew Goff, Diane Hsiung, Jennifer Hsui and Greg Savage (the “Portfolio Managers”) are primarily responsible for the day-to-day management of the Fund. Each Portfolio Manager supervises a portfolio management team. Mr. Goff, Ms. Hsiung, Ms. Hsui and Mr. Savage have been Portfolio Managers of the Fund since 2013, 2008, 2012 and 2008, respectively.
Purchase and Sale of Fund Shares
The Fund is an exchange-traded fund (commonly referred to as an “ETF”). Individual shares of the Fund are listed on a national securities exchange. Most investors will buy and sell shares of the Fund through a broker-dealer. The price of Fund shares is based on market price, and because ETF shares trade at market prices rather than at NAV, shares may trade at a price greater than NAV (a premium) or less than NAV (a discount). The Fund will only issue or redeem shares that have been aggregated into blocks of 50,000 shares or multiples thereof (“Creation Units”) to Authorized Participants who have entered into agreements with the Fund's distributor. The Fund generally will issue or redeem Creation Units in return for a designated portfolio of securities (and an amount of cash) that the Fund specifies each day.
Tax Information
The Fund intends to make distributions that may be taxable to you as ordinary income or capital gains, unless you are investing through a tax-deferred arrangement such as a 401(k) plan or an IRA.
Payments to Broker-Dealers and other Financial Intermediaries
If you purchase shares of the Fund through a broker-dealer or other financial intermediary (such as a bank), BFA or other related companies may pay the intermediary for marketing activities and presentations, educational training programs, conferences, the development of technology platforms and reporting systems or other services related to the sale or promotion of the Fund. These payments may create a conflict of interest by influencing the broker-dealer or other intermediary and your salesperson to recommend the Fund over another investment. Ask your salesperson or visit your financial intermediary’s website for more information.
S-8

[THIS PAGE INTENTIONALLY LEFT BLANK]

[THIS PAGE INTENTIONALLY LEFT BLANK]

For more information visit www.iShares.com or call 1-800-474-2737
IS-SP-IXJ-0815
Investment Company Act file No.: 811-09729
 GRAPHIC 2 g60307br2015.gif GRAPHIC begin 644 g60307br2015.gif M1TE&.#EA?0`2`/```````````"'Y!`$```$`+`````!]`!(```+^A(\0R^T/ MHYPIS8LSJU7[+W$62%[(PI6J=@;="F^'T\ZF#;TNCLYMS]/1=#^@8K0Q>I2EK%";:'EE4JI8Q6]$]I6UWS/N:\SR(D]CU_S.BZWX?6TJ MY>56YK>70S1W%U8H1I5X4J7(-\2WU33V%,G&I=CVJ&8HJ1D'ER@J&,H6B;4) MQGDH])#&9*IE]RIKJ0H8"EE;F=IZFI7;"$H,5L[]NP;A$K[ M&1A]W2R\2O(+]OWOQA.Y;,8+*`JB;. GRAPHIC 3 g60307imgb6f56d8d1.gif GRAPHIC begin 644 g60307imgb6f56d8d1.gif M1TE&.#EAG``K`/,``````!$1$2(B(C,S,T1$1%55569F9G=W=XB(B)F9F:JJ MJKN[N\S,S-W=W>[N[@```"'Y!`$```\`+`````"<`"L```3^\,E)J[TXZ\V[ M[X7SC61IGFAJ`0.COG`LSP0`%,JL[WS_&+8@X7!(+(Y'GW+)G"""T&A4,$R( MFMALJ2'M>F^)4E`K)F]J4,'7.UAXNN:.+9Y13`L&]3IZN&;&$H!T&'.#%WII M1@D':'L#?BN%$Y*!'``7E).8ERL/E)F>G!2@,`E>`08*(@T*C%^/A**Q@J-1 MD[:A4+>ZN;Q2@;B_.HAL!VX2"05=`[$:@*!CT873<]*!E.%@@,4H!!@L"!"D M0<&$\?3!:[CSX3R3.M_)N\>CY4L^#((<2'=2V\ETN?!)?"HQ)T-I))WJS$?4 MP[FC-@;P8\;T(RV5V&RA%/80(MIN56N!)*5!(]@!!VQ`*OCGC[=.-SUA(K%2 M,.`F"QH=':#LF`RZFPQE20R6A0#',2!WE#PYS]$"G$.;87"@@.(O2T6K)N,` M"1(B!&@"(%C-L%S-9570Q6WU[`;>,!P<"$"V]E]-1&O;WJH.N>&_;>6IYJ?=//A%"W<'R@7Y2B_K(')K/">FA$L5 M.WVVVLG48$!>QUFWW#M"[?2<5E6)Q.`W^*G7C53-94=&`[)]AUY[0KTDGH9[ M\`?=A@LVI1499+V0X&HLCI"#BH6U*..,--9HXXTXYJ@C4TRT%=D;,0+YHTI9 M;-/62MM8F(]U!D((W7-9'5BAA4:R@]U^5U:7PCQI.?E+1!^*$V9)O907D8/L MV56(7[8)(()MEEF=G-&X%6<_=IYPY(2VK7-F0VB:J&&9N("(:)Y[ H@KD&H"BTYY9T\YE9:)IX8JJIB9G21V&E.X:J6X"BEAJ8J:B:$0$`.S\_ ` end GRAPHIC 4 g60307isharesbr2015.jpg GRAPHIC begin 644 g60307isharesbr2015.jpg M_]C_X``02D9)1@`!`0$`9`!D``#_X@H@24-#7U!23T9)3$4``0$```H0```` M``(0``!M;G1R4D="(%A96B````````````````!A8W-P05!03``````````` M````````````````````````]M4``0````#3+``````````````````````` M``````````````````````````````````````````````ID97-C````_``` M`'QC<')T```!>````"AW='!T```!H````!1B:W!T```!M````!1R6%E:```! MR````!1G6%E:```!W````!1B6%E:```!\````!1R5%)#```"!```"`QG5%)# M```"!```"`QB5%)#```"!```"`QD97-C`````````")!"!3;V9T=V%R92`R M,#$Q`%A96B````````#S40`!`````1;,6%E:(`````````````````````!8 M65H@````````;Z(``#CU```#D%A96B````````!BF0``MX4``!C:6%E:(``` M`````"2@```/A```ML]C=7)V````````!``````%``H`#P`4`!D`'@`C`"@` M+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0": M`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T! M$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I M`;$!N0'!`$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<" M<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-: M`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$ M?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07% M!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&09!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[ M"1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP* M\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT- M#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/ M>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$)%ZX7TA?W M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL; M8QN*&[(;VAP"'"H<4AQ['*,0!YJ'I0>OA[I M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B--@U M$S5--8Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546: M1=Y&(D9G1JM&\$25^!8+UA]6,M9 M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9O5\/7V%?LV`% M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\> M;WAOT7`K<(9PX'$Z<95Q\')+%V/G:;=OAW M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$ M?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2( M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_ MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB: MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16 MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:QK_UP'#`[,%GP>/"7\+;PUC# MU,11Q,[%2\7(QD;&P\=!Q[_(/%$XIZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[< M_VW____;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<'"`D M+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-&#(A M'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R M,C(R,C(R,O_``!$(`$H`H`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0`````` M`````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4 ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C MY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4& M!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R M@0@40I&AL<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JB MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR M\_3U]O?X^?K_V@`,`P$``A$#$0`_`/'Z***"@HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"I['_`)"%M_UU7^8J"I['_D(6W_75?YB@""BBB@#H MO`[:`GBJU/B6-I--PVY55F&['RY"\D9["NJ\+^#]#\7_`!1U"ULXYHM`M@UP ML3;E9E^4!>?F`).>><#L:F^!FJ7D/C%M,CFQ9SP/))'M'S,`,'.,U%JGBR?P M9\:]8U2*(31F9HIXLXWQD*2`>QR`?PH$3ZE\0M'T;6KO2[;P'HAL;:9H2DT" MF5]IQEFP>>.X/XTO@.Y\/^(OB9<6B^&['^S;X&2**>/W^'?Q9!>)Q!JQ7)V_N;@<=QT?'KS]17*^#O!]WX*^-5CIUS()HGMY9()U& M!(FQAT[$$8(H`XOXAZ4(OB'K5KIE@$MX'4B*VAPL8V+V48`S7(5[OXB^)NHZ M%\3WT;3K*S2R^TQ)<[H_GG9@NYBP/!P0!]!]*Q_C!90:!\0=)U;3K*"2XN%$ MKV[Q;DEE5L`E1U)R,^N*`/*!8WC6_P!H%K.8/^>@C.W\^E5P"2`!DGM7OWA/ M5_BK<^(+&35M.?\`L>5PDT&)9W4DS1);3-*HW,BH20.N<4EO:W%VY2VMY9G`R5C0 ML?TKW7X@_$&?PGXKN])T/3+-[J]5'O+BY#,79D"*HP1C"A>I[GCUT_$6A^)/ M"GAG2M&\`V&'()O;J)8][%0,$ENNXEC[8QTH`^K^#/#VL>+[2.TU*WO+>._DPJDQ-)L<,5 MXP1AO;G'I4OC<_$'0]32_P#"HADT&*)=EG;0(P0`<@IC)!]5[>E`7/G8QR"( M2E&\LG:&QP3Z9IM;U]XJO[W1Y-*EB@6%IWF)"G<"SEB.3ZG_`#SG!H&%%%%` M!4]C_P`A"V_ZZK_,5!4]C_R$+;_KJO\`,4`04444`>I?`S3+V7QD=22W=K*& M&2.2;^%6(&!2^*O`FJZ_\5=6M`8[1[I7N;1[@X2<+M&`1TZ^G:O+*`2""#@C MO0(]-T'X1^,+/Q%9W-W!%86UM.DKW9ND(55.20%.)IT.5=RK$[3W`XY]47,J(-^,[?F(YQ0!U/QD= MH_B?>NAPRQPD'T.Q:]`\4VDGQ9\):7JGAJ]B74;0'S[3SMA!8#"XA8I)&XP5-1Q32V\@DAD>.0=&1B"/Q%`'9:A\/O%M@ M^GP:N%M1?WL=G");M7R[GAB%)^48Y/TKT/P!I'Q%\*ZY%::H0GAZ(-YS7%RC MQ(@!P4.(-O;!=/+8EZ=J,D>M+/]EO+P0(B"(C>"77.,XP2>O0XKS>*]NH+6>UBN98[>X*F:)7(6 M3;G;N'?&3C-04"/:/'5@?$^A3G1+VWORFK2W$SM=PH%S"F=I8J&4'*@CL._6 MDM;7PV/#%MX5NM1LI+JP2+49(=K[S,"7F3=MV,#&0@`;.5_+QBB@#V?[;J__ M``L+SK[4K>X\./+=R6&RZB95C-M*$$8R60;<`\8SC/)&707FFQZ?J-U$T4_A MAM#V6EBDWE/&1(GF1OU/F$Y);^+MP./%J*`/<-6NI9]$E7PG?6T,S0VHTPPS MB*862AMT>YFR'$A^;G)&.W%0ZOJ3RVFH#P=J%I%KJWL,NH/;S1QFX`@4,5+$ M!D$@;(&02<\YKQ6B@#V%;F&?PU:6MM=V\7BI]*E6"6I'''7GVZ#`'I6510,*GL?^0A;?\`75?Y MBH*GL?\`D(6W_75?YB@""BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH AHH`****`"I['_D(6W_75?YBH*GL?^0A;?]=5_F*`/__9 ` end GRAPHIC 5 g60307ixj.jpg GRAPHIC begin 644 g60307ixj.jpg M_]C_X``02D9)1@`!`0$`9`!D``#_X@H@24-#7U!23T9)3$4``0$```H0```` M``(0``!M;G1R4D="(%A96B````````````````!A8W-P05!03``````````` M````````````````````````]M4``0````#3+``````````````````````` M``````````````````````````````````````````````ID97-C````_``` M`'QC<')T```!>````"AW='!T```!H````!1B:W!T```!M````!1R6%E:```! MR````!1G6%E:```!W````!1B6%E:```!\````!1R5%)#```"!```"`QG5%)# M```"!```"`QB5%)#```"!```"`QD97-C`````````")!"!3;V9T=V%R92`R M,#$Q`%A96B````````#S40`!`````1;,6%E:(`````````````````````!8 M65H@````````;Z(``#CU```#D%A96B````````!BF0``MX4``!C:6%E:(``` M`````"2@```/A```ML]C=7)V````````!``````%``H`#P`4`!D`'@`C`"@` M+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0": M`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T! M$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I M`;$!N0'!`$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<" M<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-: M`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$ M?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07% M!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&09!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[ M"1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP* M\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT- M#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/ M>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$)%ZX7TA?W M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL; M8QN*&[(;VAP"'"H<4AQ['*,0!YJ'I0>OA[I M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B--@U M$S5--8Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546: M1=Y&(D9G1JM&\$25^!8+UA]6,M9 M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9O5\/7V%?LV`% M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\> M;WAOT7`K<(9PX'$Z<95Q\')+%V/G:;=OAW M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$ M?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2( M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_ MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB: MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16 MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:QK_UP'#`[,%GP>/"7\+;PUC# MU,11Q,[%2\7(QD;&P\=!Q[_(/%$XIZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[< M_VW____;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<'"`D M+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-&#(A M'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R M,C(R,C(R,O_``!$(`(P!3`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0`````` M`````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4 ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C MY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4& M!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R M@0@40I&AL<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JB MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR M\_3U]O?X^?K_V@`,`P$``A$#$0`_`/9];\00:+-9PR#Y[AF9F(8K#"F-\C8! MPHRHR<#+#)`R12N_$]S!=3^1IZW-O'QV M-:&GZSIVJO*EC>13M"%,@0_=#9QGZ[3^55=,\-V6E7[7EN\S2NK!_,8'ZA!;VT=M!>"V66.6::W(!)$BA8_O`@'))^@' M(8XI7$TU[KDUN+^XM=3EOFA$2S'=':FV)#;,XP#\V[^^,9SQ0!WE9%M_R..I M?]@^T_\`1EQ6!X2OIC?7MGEI'6-VLRY*)Y6X.IV$LP5O-&#D_*N."N#J:0;\ M^+-4_M!+9)/L-IM%N[,,;[CKD#F@#HJ***`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K.U+5TTRXM(Y879 M+B01^8&4!22`."03USQG`!/;G1K,U71(=8VIUUC3OMUFXDA)8+L8,2!TZ'C(P<'G!&<52N/%-C;VFGS.KA[Z`W M$4!*A]H0-C&>6R54`9R6';)%K3='73%Q%=W,FY]\GF;/WA"*@SA1C`1>F/?- M02>&K5Q9`7%R@M8HXAM*_.(V5DW94\AE!XQGOD4`6M(U1-7M#[:"V" M&.!G:1U`.1GU!J_69I.AVVC-.;>29_.P6\T@\@DYR`"22QR3D]!T`%:=`!11 M10`4444`%%9NJZY8Z*%:]>15,;RLRQ,P2-,;W8@<*-PR3ZU'<^)-+L[J6"XG M:/RMP>0Q-L#+&9"N[&-P0%L>E`&M61;?\CCJ7_8/M/\`T9<58L-7M=28I!Y@ MD5=SHZ%2GS,F#[Y1ORJO;?\`(XZE_P!@^T_]&7%`&O1110`444A('4T`+133 M(@C\PNH3&=Q/&/7-*64'!(!/J:`%HIJNK@%&#`C((.>*=0`4444`%%%%`!11 M10!')/%%)%')*B/*Q6-6;!<@$D#U.`3^%0PZC97'G^3=0R?9R1-L<'81G.?Q M!'X'TI+RT:XN]/F79_HTYD;/7!C=./Q85CZ'HVHZ1,D9^F0?RK(&CWPDT\,MM(GFFYOF\UE:27((Q\IRBGD`D?<0 M9P#DT/1;S2M2NW+6ZV<^66.,DE#P$497.``W?'/"KCD`Z"BBB@`HHHH`**0L MJ@$L`"<M4M;2670-06W:43-;2>6820^[ M:<;<>"<4`=96!XY9D^'_B1E)5AI5T00<$' MRFJK8+>VOB^X1H[V:SE9RDCAPBL1N8]""!M5`_\`/W_\_=Q_P!_#_C5>B@#[8BNI]$0M&'N M-.C0YMAC?$!DYC)QD?[)/`^Z1@*>DDECA7=+(B+ZLP`KG+[_`(\+G_KDW\C4 M^J:5)%7D56"L'DR^UNNP.&QWZ4`;H="@<.I0@$-G@YH:1$ M.&=03C@GUX%LWNI:A*L4C[V+0.9(@BE0HB*]6`"M-D'^)LCKD`';@@C(.12U1T=)HM(MXI M[=;=XUV")?X5!(7^)OX0#]X_4U>H`PO$5EJNH/:06<-G+8!B]W%/<-$9<8*I MQ&WR9Y;IG`'0FJYT"[;56#?9GTYK\WQ+.QD),6SRRI7&-W.<].,=ZZ6B@#E] M"\.7FEWEWYTL'V*[5WD@MR4578)PJ@#`7#@,#DAAD9&:2UL(-*U[6ULIOLH_ MLZUD,LS-*$P]QDG9<<$4`5IM2U: MT\,6D\FR34;B9$"B'#;7?@;"P^<)U!.`0?2LR7Q/JMQ:07%H]F@D2$,KH?XH M#.SJ2P&,#`!]#D^F?>?%KX8SRR)>ZI;RN/W;B73IGX#9QS'TR,_45&WQ9^%C M.CMJ=L6CC$2$Z;-E4'11^[X'M0!V^@ZDVJZ6EU(5\QCED5679G#*.><[64YZ M'.1Q5/Q#I4]_,LL$"RXM)(G5F`$@,D+&/D_Q*CCT]2*-(\1>'KFTCFTQA':7 M`\]91:20Q-D9W%BH49]S[55\=>*W\,^`;_Q'IHMKMH!&8PS;HWW2JAY4_P"T M>_:@"06VBT[[)(D( M]0U6SLO[)TJ/[1.D6_;(=NY@,XW<]:`/;/"EE?Z?;W,%[;+$"X=7#`ERM)>6%]/KEI=QK;^1;,T@_?,K/F-UVLNT@\D'=U`R,=<@% MFYUS2K226.>_MTDAQYB%QEP2-(J,@5P2P9=RX^ MJ\_3FL`>'M5_M:\NA-!"EVKJYCF^N8B!)# M;R2)D9&0I(KY;_X7[XZ_Y^;+_P`!5KZ?U_\`Y%O5/^O27_T`U\(T`>G_`/"_ M?'7_`#\V7_@*M?1&D:QJ@TRUN+I4OEE@20F,".4$KGIPKT?_`*"*`.G@N8YX()@=HF4,BM@'D9Q]<5+D`@$C)Z"N:ELGO/\` MA'R-/,T<21R/;#P M%E(W$*""2VTY#=%'`.<@'2>;'Q^\7YB0.>I'7^1I^5G,URPX)8.7$9X."H&>1BN$^+?Q4USP%K]C8:7::=-%/:^ M.*\^_P"&CO&'_0-T/_OQ-_\`':`/;]3\/7$VEP1P69::.[N&V[UQY,DK,1@D M9+#;P&4\G)'-=5:M,UG`UQ&L/_#7XI^)O'-WJ$-S#I-L M+5$=3%;2'=DD8.9?:O5+#4KBYN6@N;6.$[2Z&.8R`@$`YRJX/(]>]`'C6O\` M[0EWHOB35-*7P[!*ME=RVPD-T07".5SC;QG%9W_#2][_`-"Q;_\`@6?_`(FO M*/'?_)0_$O\`V%;K_P!&M7/T`?8W@KQ_<^*?#]MJ\^CB""9G4^1/YC)M8C)4 M@<8&>"3[5J>,;F*\^&GB.>$L8VTJ[QO1D/$3CD,`1TKAO@Q_R3.P_P"NLW_H MPUVWB[_DF/B+_L%7?_HMZ`/BBBBB@#[9OO\`CPN?^N3?R-97Q2\>77@#0[*_ MM+*&Z>XN?)*RL0`-I.>/I6K??\>%S_UR;^1KSW]I'_D3M)_["'_M-J`.6_X: M4UG_`*`%A_W]>ND\#_&_5O%OB>+29-&LH@\;ON69QRJY`S@X_(U\VUZ%\%?^ M2E6G_7";_P!`-`'U7::Q'/+%;SP36]S(2%4J71B%R2''&.N-VTG'2M*L&'_D M(V7_`%T;_P!%O6]0`5REWKNK"\G:S6V>,7CV$4$J,"7$)=7+9Z;\#&/N\YS7 M5UG_`-BZ?_:9U'R6^TE_,SYK[=^S9OV9V[MGR[L9QQF@#(\/^()[Z:]@O'4S M6>]#$J#S)"C')PI*\*8P0#]XGID57M_$$0\6:C)_9VJX:QM1C[$^1B2XZC'3 MG]#6_9:)IVG7'GVEOY4FSR^'8C&%'0G&<(@)ZG:.:@MO^1QU+_L'VG_HRXH` M^2+SX;^-);V>1/#&IE7D9@?(/0FH?^%9^-O^A8U/_OP:^U**`/.?!:SZ7X+T MBQO;#4(KF"V5)(S92G:P[9"XJI\0OMFM?##5=#T_2-4FOIG4QJ+-P&`N%?J1 M_=!KU&B@#XK_`.%9^-O^A8U/_OP:OZ'\._&5IK^FW,_AK4DAANHI';R"<*&! M)_*OL6B@#F4U!(Y%(O'1_LO_A!;+58_];]LW:KT4`?-?_"0_'K_`)X:G_X+(/\`XW71^"M9^*MQKK)XJ.K0 M:=Y+$.FF19WY&!\L1/3->XT4`SD#*<9YX]"*[ZOC?XP?\`)5]?_P"NR?\`HM:` M/H#_`(7MX!_Z"=Q_X"2?X5O:)\0=#\1V3WFD?;+JW20Q,ZV[`!@`2.<=F'YU M\55]&?`+_D1+[_L)R?\`HJ*@#TS5M>CO-'U&UM].U.25X)(@$M&(W%.!D<=Q M7RE_PK/QM_T+&I_]^#7V#HWW;S_KX_\`::5IT`?%?_"L_&W_`$+&I_\`?@U] M0Z7<+*&6TU!9(X$5E^PS<$*`1]VNSHH`X;6?%6L:5X8@_L+PYJ%_J,8CC M\F6UD1<8PQSBN2_X61\4/^B/_B)=ZG!;W_@9[&UD;$ES MY,LGEC'7:.37<_\`"1W$80-IEW+C:'9+6=2>F2%*?4XW?C70T4`?._QJT#7O M&'B33[O1=`U2>&&T\IV-JRX;>QQS[$5YG_PK/QM_T+&I_P#?@U]J44`?//P: M\.:[X7U#59-9T74;5)XHUC)M7;<03G[H/K7KT.J+;7R3&QU)T\MU.RQEX)*D M=5'H:ZBB@#Y"\5^`?%^I^,=;U"U\-:F]M=:A/-$Q@(RC2,P./H161_PK/QM_ MT+&I_P#?@U]J44`>3?#"SOM`\"6>GZIINH6]W')*6C-G*V`7)'(4CI72>)=0 M>\\$ZUI=MIFJ2W-QI]Q#$!92`,[HP`R0.Y%=K10!\5_\*S\;?]"QJ?\`WX-' M_"L_&W_0L:G_`-^#7VI10!R-U=>99SQI:WY9HV`'V&;DD?[MS44`?%?_"L_&W_0L:G_`-^#79?"[P;X MF\/^.;;4-4T#4K>U2*16D-LS8)4@<`$U]144`+?0>:L-Q"-Q7;/$8V_(]JLT4`-9T3;O=5W':,G&3Z4;UW[-PW MXSMSSCUKCO%:?;8[6TU'2I#-.)(CD MM>ZY<6UQ9W'GS:@[/=)"RC[*UL4P)<8[[=N<[N<=Z`.VCECE56CD1U8;E*L" M"/45EVW_`"..I?\`8/M/_1EQ6'X6M[^VU"^A>TEA297>WGGBP8T)#J"%`3EI M9"5&""I!R,&M'2(;R'Q9JBWMVEU(;&T(9(?+P-]QQC)H`Z*BBB@`HHHH`*** M*`"BBB@`HHHH`*^-_C!_R5?7_P#KLG_HM:^R*^?/'_P6\4^)?'.J:Q8/IXM; MJ16C$L[*V`BCD;3W%`'@=?1GP"_Y$2^_["I`JK>>*;>RN9TDM+IX(7:$SQJK`RK$92@& M<_=&`<8W<4`;M9%M_P`CCJ7_`&#[3_T9<4:-K\&LQR/%'M6$$2N'5D5@S*5# M`X/"[OHRGO4=E-%/XOU-HI4D`L+0$HP/_+2XH`VZ***`"BBB@`HHHH`****` M"BBB@"&>9XW11"Y5@=TH*[8L#JV2#^0/X5S>BZC<74.G31:HUU;3W\B!FV,[ MQ^2[`-M`VDLN\#@@%0?2NJHH`Y&?7I3XQAAAOE>P:,#9&5;.(YF9@H!9AE%& MX'`(VXR361'X@O;:],CZRUU8+/Y>^-HY"8PJ2%@0J@[BVW'!!RJAN*]%HH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`YS5O!]IJ<:[;N^AE7`60W4DF!O5B/F;OL7\0#VJ2/PV\6IB9;P?8Q=_;! M`8LN9?*\OE]W*_Q8QG/?'%;]%`&!I?AG^S]1N;N6]-T+E&\])$^^[;,D\XV_ M*<+CC>PSCBM:UTZRL2YL[.WMR^-_DQ*F[&<9P.>I_.K-%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%5[VY:TM6F2VFN7!55BA`+,68`= M>`!G))Z`$U8KDOB7K5YH/@>[O;%PDYDAAW'/"O(JM@@@@X)Y[4`6W\76ZV27 M*6-U(1'/+-&@7=$D+[)#UPW/3;G<.15I?$5N^IK:+!,86G^S"Z&WRS+Y?F;> MN<;>^,9XKS>[U^X;PGX>U&&WM;>34H)]+DCAC(2.'?M&P$G#`+QDD'8E5+%9!J*X'SB3R2F,_W?XO7/?'%`'5^'O$$/B*T:ZMXU2+"E<3H MY(89&0I.TXQP>:DUK6AHMN9WLKF>%(WFE>(#$:)C.*@B\767V&YO+N&:SA@MDO`9MOSQ/G:1@GDE<;>N2/6NTN8XY',:7+` M;&81F4X&<[0H(W8QN&.M5?!$S77A&RNW"A[II;EPHP`TDC.0/;+''MZUQMOX MFO+[XS7^@74%M+:?-9HS*V^.+R!*P7G'S-C)QR`!V%`'8Q>+8)("[6-TDCI# M);Q-LW3+,Q5".<#D<@XP.M-;Q5(/LQ32+EUFN?LA_>1ADE#E6&W=D@!6;(XV MC-<)I^I3W7AG5]4E6,W.A"WAM#MX(AK?.$:.V?8K%75V!)W8 M4@1ME3R/E]:WYY#%;RR+C*(6&?85X3X?\<:G<^&Y=?E@LSJ%G=0S>9L;]\TZ M.K[_`)N@"J`!C&T#H,4`>M+XMLY!;RPVUR]O)'`\LN%`A$S;4#`G.<]<9QWJ M>P\1V^H:O)IZ02HP\_9(Q4A_)D$^+6OW>AZ%IRVR0R1WEX(;B.4$K)&(WB:.)4\0VMG/>!5(PR,'&SG@'.TYSP!C!YH`Z]O%MI' MY\DMM3+%(5)#;% M<8*D@C:ZFN'\/LE_XKU?0KF"*2PTM+F.&,K]]9G!8/V(`RHZ<'G)YKIO!5I% M;^%K2Y3>9;]%O)WD=G+2.H/4DG``51[*.O6@"YJ&M#3KV&"2RN7BD>*,W"@; M%:1]BCDY8YY.!P"">*98^((;[4!:K;S1I()3!,^W;+Y3A'Q@Y')XR.1DUP_B M;Q9?V/Q>TC2%BMI;4+;[!*K$HTTC([C!`W;1@$YQD^IJ_P"%;EYO&VH:4RH+ M;1_/%MM&#B616.[UQT&,<=YK=TG4IM<^&WB76KI8UNKRWG\Q8P0BA8`H`!)/;/)/)/L``=O>:G'9:A MIUF\,SM?2O$CHN40K&S_`#'MD*<>M6;F?[-:33^5)+Y2,_EQ+N=\#.%'(VDP_ MH<*1CU^AKS+3_%-VOP_MM?2VM5O--U-H(QM8K()(QO9\MDL2Y8D$9('OGNX( M%MK'P;"A)"SCENI/V28DG\:`-6VUH7&L-ISV5S`Y222)Y`,2+&X1C@'(!+`K MG&X:_9W MD5L=K3XF56#[8IO+1.N-H!)QCJ2>YJ_\6M?N]#T+3EMDADCO+P0W$@#J=*U&/5M/2\BC>-69T*L02"C%#R"01E3@CJ,&JL^NI;:NEC/:7,<Z1CM4=E'0"N2M M_$UY??&:_P!`NH+:6T^:S1F5M\<7D"5@O./F;&3CD`#L*`.YT_Q%%?I,WV.Z MB9+9+N-&4,TL3;MI4*3S\I^7J,CUJ.?Q59P:#INJM#,5U$0F&'`W_O`#SS@; M0